The network
Board Members
The Capital Network is led by a Board comprised of accomplished and respected entrepreneurs, investors and sponsors.
|
Leslie Williams Recognized in 2006 as one of the top 100 leaders in life sciences by PharmaVOICE magazine, Leslie Williams has more than 20 years of industry experience in healthcare, management, commercial product development and marketing. Her two decades-plus career runs the gamut from critical care nursing to corporate executive leadership positions, including president and chief executive officer of Ventaira Pharmaceuticals. Williams joined the specialty pharmaceutical company, Ventaira, in 2003 in the dual roles of vice president of business and commercial development, and chief operating officer. She was quickly promoted to president and chief executive officer, a job she held from 2004 to 2007. Under her leadership, the company became a significant player in the pulmonary-drug-delivery market and the company was sold at the end of 2007. Prior to Ventaira, Williams was director of marketing for INO Therapeutics, Inc., where she played a significant role in the development of INOmax (nitric oxide), a drug for treating pulmonary hypertension. Among her many accomplishments she helped orchestrate the New Drug Application submission to the FDA for INOmax for inhalation. Responsible for the commercial aspects of INOmax's U.S. market introduction, from setting objectives and strategy to developing key constituency groups and expert advisory boards, as well as representing INO Therapeutics on Capitol Hill, Williams also assisted with expansion of the INO-therapy platform into the European marketplace. (The company was acquired by Ikaria Holdings in 2007 for some $670 million.) Williams's prior pharmaceutical industry experience includes commercial positions at Merck and GlaxoSmithKline, and drug-delivery and monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.) where she also discovered, developed and managed "OptimizOR", an efficiency and scheduling tool utilizing mathematical modeling. Leslie was a Venture Partner with Battelle Ventures. As a venture partner she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A strategy and execution. Williams serves on the Board of CDI Bioscience, a company that has developed an innovative technology for increasing the yield of bioproducts. She also serves on the board of Hepregen, an MIT spin out, which has developed a stable and highly functional micro- liver model to be used for ADME/Toxicity testing and drug screening. Leslie is currently President and CEO of ImmusanT, Inc., a Boston-area biopharma startup. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree biology with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa. Leslie left active patient care to seek and evaluate new technologies that impact health and the life sciences.
|
